Shmuel Yaccoby, Ph.D.


Professor of Medicine and Physiology


Ph.D., Department of Animal Science, The Hebrew University of Jerusalem, Israel
Post –doctoral study at the Department of Physiology-Biophysics, University of Arkansas for Medical Sciences
Research Fellow, Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences
Research interest: Dr. Yaccoby seeks to elucidate the roles of various cells in the bone marrow microenvironment, such as bone and neovascular endothelial cells, in the pathogenesis of multiple myeloma. He is also studying the interaction between human hematopoietic stem cells and bone cells.

Selected Publications:

Yaccoby S, Wezeman MJ, Henderson A, Fox MH, Qing Y, Barlogie B, Epstein J: Cancer and the microenvironment: Myeloma-osteoclast interactions as a model. Cancer Res. 64: 2016-2023, 2004. PMID: 15026338 

Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy, JD Jr: Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple growth in-vivo. Blood 109:2106-11, 2007. PMID: 17068150

Li X, Pennisi A, and Yaccoby S. Role of decorin in the antimyeloma effect of osteoblasts. Blood 112:159-168, 2008. PMID: 18436739

Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol. 84:6-14, 2009. PMID: 18980173

Pennisi A, Ling W, Li X, Khan S, Shaughnessy JD, Barlogie B, Yaccoby S. The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood. 114:1803-1812, 2009. PMID: 19597185.

Yaccoby S. Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol, 149:311-321, 2010. Invited Review. PMID: 20230410

Yaccoby S. Role of proteasome in bone formation and osteoclastogenesis. IBMS BoneKEy. April;7(4):147-55, 2010. Invited Perspective.